ENHANCE was a surrogate endpoint trial conducted in 720 patients with Heterozygous Familial Hypercholesterolemia. This study showed no significant difference in the primary endpoint between patients treated with ezetimibe plus simvastatin versus patients treated with simvastatin alone over a two-year period.
References and Resources
Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients With Heterozygous Familial Hypercholesterolemia (ENHANCE)
Thanks to ReachMD for providing the audio clips on Dr. Matthew Sorrentino, Dr. Steven Nissen and Dr. Roger Blumenthal’s debate surrounding the ENHANCE trial.
For the full audio program, please visit ReachMD.com
Sponsored by The Doctor’s Channel